Application 206144
- Type
- ANDA
- Sponsor
- SANDOZ INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CEFIXIME | CEFIXIME | FOR SUSPENSION;ORAL | 100MG/5ML | No | No |
| 002 | CEFIXIME | CEFIXIME | FOR SUSPENSION;ORAL | 200MG/5ML | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A206144-001 | CEFIXIME | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | ||
| A206144-002 | CEFIXIME | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | bb7c543d1eb4… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 782e0a99824c… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 87673890dc5c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 5aa47cf7b7d7… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 8869cabd3fbd… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | c0c555d07b60… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3f01610625f2… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | b00525d2431f… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | ea99ee380514… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 6a51e52b5d6a… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 1c564ffb4f44… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | ea1830bbd6c7… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | a72a2bbeb626… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 9b2671bbb829… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | a67488948f0b… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3f0d92c62455… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 053a50430f4f… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3bdfa0b2c4d7… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A206144-001 | CEFIXIME | 100MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3a93d1ddd44b… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A206144-002 | CEFIXIME | 200MG/5ML | FOR SUSPENSION / ORAL | 2017-11-17 | 3a93d1ddd44b… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CEFIXIME | CEFIXIME | REMEDYREPACK INC. | 3194433c-c04e-442b-9668-fbeb0a15bac7 | 2026-08-05 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |
| CEFIXIME | CEFIXIME | REMEDYREPACK INC. | d6718f02-8eea-4c2f-9aa2-65121d9a6e4c | 2026-07-28 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |
| Cefixime | CEFIXIME | Rising Pharma Holdings, Inc. | b5a3c547-3bc7-4856-af9c-1bead294f5d9 | 2026-04-06 | Warnings, Adverse reactions | Cefixime CEFIXIME |
| Cefixime | CEFIXIME | Aurobindo Pharma Limited | 9cdb156f-7a99-413e-b49a-ffafaf9e93fe | 2026-03-25 | Warnings, Adverse reactions | Cefixime CEFIXIME |
| Cefixime 400 mg | CEFIXIME | Health Department, Oklahoma State | f0fdb14b-e4fb-707e-e053-2a95a90a9049 | 2025-12-20 | Warnings | CEFIXIME |
| CEFIXIME | CEFIXIME | Lupin Pharmaceuticals, Inc. | 6d68dbd9-7d75-4ff1-91db-79ff8ae879ec | 2025-10-14 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |
| Cefixime | CEFIXIME | Aurobindo Pharma Limited | 068e6edd-a5fe-40d8-8dcf-ac82b78dced4 | 2024-02-14 | Warnings, Adverse reactions | Cefixime CEFIXIME |
| CEFIXIME | CEFIXIME | Ascend Laboratories, LLC | 6f1df975-f825-4301-87da-d7eba56a6890 | 2022-05-31 | Warnings, Adverse reactions | CEFIXIME CEFIXIME |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.